Dialysis News and Research

Latest Dialysis News and Research

Rockwell Medical first-quarter sales up 17.1%

Rockwell Medical, a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease (ESRD), chronic kidney disease (CKD) and iron deficiency anemia, reported first quarter 2010 results today.

5 May 2010

NxStage Medical first-quarter net revenue increases 20% to $40.4 million

NxStage Medical, Inc., a leading manufacturer of innovative dialysis products, today reported financial results for the first quarter of 2010 ended March 31, 2010, with total revenue above the top end of its guidance range.

5 May 2010

Quark to present poster on predicting risk of DGF following machine perfusion of renal transplants at ATC 2010

Quark Pharmaceuticals, Inc., the world leader in clinical development of RNAi-based therapeutics, announced today the presentation of a poster at the 2010 American Transplant Congress titled, "A Nomogram for Predicting Risk of Delayed Graft Function Following Machine Perfusion of Renal Transplants."

5 May 2010

Fresenius Medical Care's first-quarter net revenue up 13% to $2,882 million

Fresenius Medical Care AG & Co. KGaA, the world's largest provider of dialysis products and services, today announced its results for the first quarter of 2010.

4 May 2010

Data from Phase IV study of Bystolic tablets in Hispanic patients with hypertension presented at ASH 2010

Forest Laboratories, Inc. today presented data from a Phase IV study evaluating the effects of Bystolic (nebivolol) tablets in Hispanic patients with hypertension at the 2010 annual scientific meeting of the American Society of Hypertension.

4 May 2010

Belatacept preserves kidney function in transplant recipients better than cyclosporine, says study

Two-year results from phase III clinical trials show the experimental immunosuppressive drug belatacept can better preserve kidney function in kidney transplant recipients while preventing graft rejection when compared with the standard immunosuppressive drug cyclosporine.

3 May 2010

No single immunosuppressive medication increases cancer risk in kidney transplant recipients

Drugs taken by kidney transplant recipients to prevent organ rejection carry similar risks of cancer, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology (JASN). The results suggest that no single medication is to blame for the higher incidence of cancer seen among patients who have undergone transplantation.

30 Apr 2010

$EnzymeRx reports positive results from first clinical trial of pegsitacase for refractory gout$

EnzymeRx reports positive results from first clinical trial of pegsitacase for refractory gout

EnzymeRx, LLC, a clinical-stage biotechnology company, announced top line results from its first clinical trial of pegsitacase (formerly called Uricase‑PEG 20). Pegsitacase is a pegylated uricase being developed by EnzymeRx for the treatment of refractory gout and for the management of hyperuricemia associated with tumor lysis syndrome.

30 Apr 2010

CSI announces completion of enrollment in CALCIUM 360° clinical trial for PAD

Cardiovascular Systems, Inc. (CSI), has completed patient enrollment in its prospective, randomized CALCIUM 360° clinical trial, part of the company's 360° Clinical Series. The CALCIUM 360° feasibility study is evaluating the treatment of peripheral arterial disease (PAD) behind and below the knee using CSI's Diamondback 360® System, a minimally invasive catheter for treating PAD anywhere in the leg. Dr. Nicolas Shammas, an interventional cardiologist at Trinity Medical Center, Bettendorf, Iowa, is the study's principal investigator.

30 Apr 2010

Experts see 'lump sums' in health spending's future

Los Angeles Times/Dallas Morning News: Some elite California hospitals will begin "bundling" their fees for joint replacement surgeries into a single lump sum in an attempt to rethink the current pricing system that leaves "hospitals and doctors charging separately for their services," driving "up costs while leaving no one to coordinate decisions about patient care."

30 Apr 2010

6 transplant surgeons perform 16 surgeries over 3 days in landmark domino paired kidney exchange

Chicago resident Maria Isho had been waiting for over nine years for a kidney transplant. Her body was highly sensitized, meaning that her body had built up antibodies in the blood, which made it difficult for her to find a match. To stay healthy, she endured a grueling dialysis regimen which diminished her quality of life and left her feeling physically drained.

29 Apr 2010

High dose B-vitamin therapy slows progression of diabetic nephropathy: Study

Patients with diabetic nephropathy (kidney disease caused by diabetes) who received high dose B-vitamin therapy experienced a more rapid decline in kidney function and had a higher rate of heart attack and stroke than patients who received placebo, according to a study in the April 28 issue of JAMA.

28 Apr 2010

Holtz Children's Hospital expands Pediatric Dialysis Unit

Jackson Memorial Hospital's Holtz Children's Hospital celebrated the renovation of the Pediatric Dialysis Unit Tuesday morning by honoring the Batchelor Foundation, George E. Batchelor, founder; Alonzo Mourning and Zo's Fund for Life; the Jackson Memorial Foundation Guardian Angels; and Alma Hernandez, in memory of her husband Dr. Ismael Hernandez. Together, they raised all of the $800,000 needed for the project.

28 Apr 2010

Mesa Laboratories announces acquisition of SGM Biotech

Mesa Laboratories, Inc., a Lakewood, Colorado based manufacturer of electronic instruments and disposables, today announced the acquisition of SGM Biotech, Inc., a Montana manufacturer of biological indicator products.

28 Apr 2010

CSI granted FDA unconditional IDE approval for trial of Diamondback 360 System in coronary arteries

Cardiovascular Systems, Inc., has received Food and Drug Administration unconditional Investigational Device Exemption (IDE) approval, allowing the company to proceed with ORBIT II, a pivotal trial to evaluate the safety and effectiveness of CSI's Diamondback 360® System in the coronary arteries. CSI received conditional IDE approval for the ORBIT II study in January 2010.

28 Apr 2010

AMAG Pharmaceuticals reports Feraheme net product revenues of $13.1M for first-quarter 2010

AMAG Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia and novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease, today reported unaudited consolidated financial results for the first quarter ended March 31, 2010.

28 Apr 2010

New DaVita Phosphorus Challenge tool for CKD and dialysis patients

DaVita Inc., a leading provider of kidney care services for those diagnosed with chronic kidney disease, today announced the launch of the DaVita Phosphorus Challenge, an online resource designed to serve as a core learning tool for CKD and dialysis patients.

27 Apr 2010

Healthcare reform will have negative financial impact on executives' facilities: AMN survey

Nearly three-quarters of healthcare executives surveyed earlier this month say healthcare reform will have a negative financial impact on their facilities, while more than 60 percent note that reform will have a somewhat or very detrimental effect on the quality of care their facilities are able to provide.

23 Apr 2010

Cytori announces launch of PureGraft 250 fat grafting technology at ASAPS meeting

Cytori announces the product launch of PureGraft 250, a revolutionary fat grafting technology that standardizes the graft preparation process for use in aesthetic body contouring at the American Society of Aesthetic Plastic Surgeons meeting.

23 Apr 2010

Baxter International's global sales for first-quarter advances by 11% to $3.1 billion

Baxter International Inc. today reported first quarter net income of $525 million, an increase of 2 percent from $516 million reported in the first quarter of 2009. Earnings per diluted share of $0.86 increased 4 percent from $0.83 per diluted share reported in the prior-year period. Baxter's first quarter financial results included a one-time, non-cash special charge of $39 million (or $0.07 per diluted share) related to a change in the tax treatment of post-retirement prescription drug benefits under recent U.S. healthcare reform legislation.

From Baxter International Inc. 22 Apr 2010

Dialysis News and Research

Latest Dialysis News and Research

Rockwell Medical first-quarter sales up 17.1%

NxStage Medical first-quarter net revenue increases 20% to $40.4 million

Quark to present poster on predicting risk of DGF following machine perfusion of renal transplants at ATC 2010

Fresenius Medical Care's first-quarter net revenue up 13% to $2,882 million

Data from Phase IV study of Bystolic tablets in Hispanic patients with hypertension presented at ASH 2010

Belatacept preserves kidney function in transplant recipients better than cyclosporine, says study

No single immunosuppressive medication increases cancer risk in kidney transplant recipients

EnzymeRx reports positive results from first clinical trial of pegsitacase for refractory gout

CSI announces completion of enrollment in CALCIUM 360° clinical trial for PAD

Experts see 'lump sums' in health spending's future

6 transplant surgeons perform 16 surgeries over 3 days in landmark domino paired kidney exchange

High dose B-vitamin therapy slows progression of diabetic nephropathy: Study

Holtz Children's Hospital expands Pediatric Dialysis Unit

Mesa Laboratories announces acquisition of SGM Biotech

CSI granted FDA unconditional IDE approval for trial of Diamondback 360 System in coronary arteries

AMAG Pharmaceuticals reports Feraheme net product revenues of $13.1M for first-quarter 2010

New DaVita Phosphorus Challenge tool for CKD and dialysis patients

Healthcare reform will have negative financial impact on executives' facilities: AMN survey

Cytori announces launch of PureGraft 250 fat grafting technology at ASAPS meeting

Baxter International's global sales for first-quarter advances by 11% to $3.1 billion

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Dialysis News and Research

Latest Dialysis News and Research

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Newsletters you may be interested in